Immune therapy for pharmacoresistant epilepsy: ready to go?
Despite the introduction of almost 20 new antiseizure drugs in the last several decades, approximately 30% of patients with epilepsy have pharmacoresistant seizures. Although many genetic disorders and cerebral structural lesions are known causes of difficult-to-treat epilepsy, some refractory patients do not fall into these categories. In the search for other etiologic factors, the multiple and close interactions between the immune system and epilepsy have gained substantial interest.(1.)
From the Division of Clinical Neurophysiology (S.R.), Department of Neurology, University Hospital of Basel, Switzerland; the Division of Neurology (J.A.P.), Children's Hospital of Philadelphia; and the University of Pennsylvania Perelman School of Medicine (J.A.P.), Hospital of the University of Pennsylvania, Philadelphia.
Stephan
S
Rüegg
Jessica A
JA
Panzer
D004827:Epilepsy / Q000276:immunology* / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*